Zevra Therapeutics Quarterly Cash Flow Statement
NASDAQ: ZVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zevra Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Zevra Therapeutics generated $17.0 million of operating cash flow and spent $217,000 on capital expenditures. That left free cash flow of $16.8 million, a free-cash-flow margin of 42.4% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Zevra Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 8.75M | 37.89M | 12.16M | -544.00K | 74.71M | -3.10M | -35.74M | -33.23M | -19.93M | -16.62M | -19.89M | -10.37M |
| Net Income growth (YoY) | -88.28% | — | — | — | — | — | — | — | — | — | -445.95% | — |
| Depreciation & Amortization | 364.00K | 368.00K | 362.00K | 392.00K | 1.65M | 1.65M | 1.65M | 1.62M | 1.56M | 1.56M | 787.00K | 62.00K |
| Stock-Based Compensation | 2.97M | 3.10M | 4.28M | 2.77M | 2.46M | 3.12M | 4.02M | 6.14M | 2.63M | 2.12M | 1.47M | 1.39M |
| Change in Working Capital | -3.41M | 6.09M | -6.08M | -6.61M | -9.83M | -9.58M | -2.22M | -1.00M | -3.75M | -863.00K | -1.58M | 6.99M |
| Operating Cash Flow | 17.03M | 6.14M | 5.52M | 4.71M | -3.60M | -8.22M | -16.25M | -18.14M | -19.11M | -16.16M | -16.16M | -4.63M |
| Capital Expenditures | -217.00K | -35.00K | 31.00K | -554.00K | -213.00K | -99.00K | 0 | 0 | 0 | 0 | -72.00K | -172.00K |
| Investing Cash Flow | 31.45M | 79.62M | 227.00K | -4.58M | 11.93M | 10.54M | -5.47M | -31.35M | -129.00K | 14.79M | 10.59M | -44.46M |
| Share Repurchases | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt Issued | — | — | — | 0 | — | — | 0 | 0 | 58.99M | 0 | 3.63M | 26.00M |
| Debt Repaid | 0 | -60.09M | 0 | 0 | 0 | 0 | 0 | 0 | -42.70M | 0 | -4.73M | 207.00K |
| Financing Cash Flow | 1.58M | -52.80M | 2.55M | 6.53M | 1.38M | 1.61M | 796.00K | 64.77M | 15.33M | 1.22M | 5.00M | 26.26M |
| Net Change in Cash | 49.73M | 33.19M | 7.97M | 6.73M | 10.37M | 3.56M | -20.25M | 14.78M | -3.59M | -200.00K | -220.00K | -22.93M |
| Free Cash Flow | 16.82M | 6.11M | 5.55M | 4.16M | -3.81M | -8.32M | -16.25M | -18.14M | -19.11M | -16.16M | -16.23M | -4.80M |
This table shows 12 quarterly periods of Zevra Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ZVRA's reporting calendar. What is a cash flow statement?